The role of budesonide/formoterol for maintenance and relief in the management of asthma

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 2, 2010, Pages 88-96

  Kaplan, Alan ^a   Ryan, Dermot ^b  

^a Bedford Park Medical Centre   (Canada)

^b Woodbrook Medical Centre   (United Kingdom)

Author keywords

Asthma; Exacerbation; Family practice; Inflammation; Review

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; OMALIZUMAB; SALBUTAMOL; STEROID; TERBUTALINE; THEOPHYLLINE;

ADD ON THERAPY; ARTICLE; ASTHMA; BRONCHITIS; CANDIDIASIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; HEART PALPITATION; HOARSENESS; HUMAN; INFLAMMATION; MAINTENANCE THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARYNGITIS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RHINITIS; RISK REDUCTION; SINUSITIS; TACHYCARDIA; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG COMBINATIONS; ETHANOLAMINES; GLUCOCORTICOIDS; HUMANS; MEDICATION ADHERENCE; QUALITY OF LIFE;

EID: 75749089943     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.10.011     Document Type: Article

References (97)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention - updated 2008. Available at: www.ginasthma.com. [accessed 25.04.09].
2. Partridge M.R. Asthma: 1987-2007. What have we achieved and what are the persisting challenges?. Prim Care Respir J 16 (2007) 145-148
3. Desfougeres J.-L., Sohier B., Freedman D., Annunzuata K., Lemoine A., and Poterre M. Has asthma control improved since AIRE? Results of a survey in 5 European countries. Eur Respir J 30 (2007) 249s
4. Price D., Horne R., Ryan D., Freeman D., and Lee A. ABS74: large variations in asthma control between UK general practices participating in the asthma control, concordance and tolerance (ACCT) Initiative. Prim Care Respir J 15 (2006) 206
5. Haahtela T., Tuomisto L.E., Pietinalho A., Klaukka T., Erhola M., Kaila M., et al. A 10 year asthma programme in Finland: major change for the better. Thorax 61 (2006) 663-670
6. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 170 (2004) 836-844
7. Rabe K.F., Vermeire P.A., Soriano J.B., and Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 16 (2000) 802-807
8. Partridge M.R., Van der M.T., Myrseth S.E., and Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 6 (2006) 13
9. Rabe K.F., Adachi M., Lai C.K., Soriano J.B., Vermeire P.A., Weiss K.B., et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 114 (2004) 40-47
10. Bai T.R., Vonk J.M., Postma D.S., and Boezen H.M. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 30 (2007) 452-456
11. Horne R., Price D., Cleland J., Costa R., Covey D., Gruffydd-Jones K., et al. Can asthma control be improved by understanding the patient's perspective?. BMC Pulm Med 7 (2007) 8
12. Ind P.W., Dal Negro R., Colman N.C., Fletcher C.P., Browning D., and James M.H. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 97 (2003) 555-562
13. Greening A.P., Ind P.W., Northfield M., and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys limited UK study group. Lancet 344 (1994) 219-224
14. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
15. Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) international study group. N Engl J Med 337 (1997) 1405-1411
16. Shepherd J., Rogers G., Anderson R., Main C., Thompson-Coon J., Hartwell D., et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 12 (2008) iii-iv, 1-360
17. Sovani M.P., Whale C.I., Oborne J., Cooper S., Mortimer K., Ekstrom T., et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help?. Br J Gen Pract 58 (2008) 37-43
18. Haughney J., Barnes G., Partridge M., and Cleland J. The living & breathing study: a study of patients' views of asthma and its treatment. Prim Care Respir J 13 (2004) 28-35
19. FitzGerald J.M., Boulet L.P., McIvor R.A., Zimmerman S., and Chapman K.R. Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J 13 (2006) 253-259
20. Anderson H.R., Ayres J.G., Sturdy P.M., Bland J.M., Butland B.K., Peckitt C., et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 330 (2005) 117
21. Spitzer W.O., Suissa S., Ernst P., Horwitz R.I., Habbick B., Cockcroft D., et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326 (1992) 501-506
22. Masoli M., Fabian D., Holt S., and Beasley R. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 59 (2004) 469-478
23. Masoli M, Fabian D, Holt S, Beasley R. Global burden of asthma. Developed for the Global Initiative for Asthma. Available at: http://www.ginasthma.org/ReportItem.asp?l1=2&l2=2&intId=94 [accessed June 5, 2008].
24. Pearce N., Ait-Khaled N., Beasley R., Mallol J., Keil U., Mitchell E., et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 62 (2007) 758-766
25. Thomas M., McKinley R.K., Freeman E., Foy C., and Price D. The prevalence of dysfunctional breathing in adults in the community with and without asthma. Prim Care Respir J 14 (2005) 78-82
26. National Heart Lung and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf.
27. Johnston N.W., Johnston S.L., Norman G.R., Dai J., and Sears M.R. The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 117 (2006) 557-562
28. Johnston N.W., and Sears M.R. Asthma exacerbations. 1: epidemiology. Thorax 61 (2006) 722-728
29. Johnston N.W., Mandhane P.J., Dai J., Duncan J.M., Greene J.M., Lambert K., et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 120 (2007) e702-e712
30. Svedmyr J., Nyberg E., Asbrink-Nilsson E., and Hedlin G. Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections. Acta Paediatr 84 (1995) 884-888
31. Svedmyr J., Nyberg E., Thunqvist P., Asbrink-Nilsson E., and Hedlin G. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatr 88 (1999) 42-47
32. Brunette M.G., Lands L., and Thibodeau L.P. Childhood asthma: prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection. Pediatrics 81 (1988) 624-629
33. Birring S.S. No clear benefit of parent initiated oral steroids in preschool children with viral wheeze. Thorax 59 (2004) 99
34. Bisgaard H., Hermansen M.N., Loland L., Halkjaer L.B., and Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 354 (2006) 1998-2005
35. Angus R., Reagon R., and Cheesbrough A. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. Int J Clin Pract 59 (2005) 156-162
36. Anis A.H., Lynd L.D., Wang X.H., King G., Spinelli J.J., Fitzgerald M., et al. Double trouble: impact of inappropriate use of asthma medication on the use of health care resources. CMAJ 164 (2001) 625-631
37. Nestor A., Calhoun A.C., Dickson M., and Kalik C.A. Cross-sectional analysis of the relationship between national guideline recommended asthma drug therapy and emergency/hospital use within a managed care population. Ann Allergy Asthma Immunol 81 (1998) 327-330
38. Haahtela T., Jarvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331 (1994) 700-705
39. Selroos O., Pietinalho A., Lofroos A.B., and Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 108 (1995) 1228-1234
40. Selroos O., Lofroos A.B., Pietinalho A., and Riska H. Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real-life study. Respir Med 98 (2004) 254-262
41. FitzGerald J.M., Becker A., Sears M.R., Mink S., Chung K., and Lee J. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 59 (2004) 550-556
42. Garrett J., Williams S., Wong C., and Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child 79 (1998) 12-17
43. Harrison T.W., Oborne J., Newton S., and Tattersfield A.E. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363 (2004) 271-275
44. Foresi A., Morelli M.C., and Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 117 (2000) 440-446
45. Tattersfield A.E., Postma D.S., Barnes P.J., Svensson K., Bauer C.A., O'Byrne P.M., et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET international study group. Am J Respir Crit Care Med 160 (1999) 594-599
46. Woodcock A.A., Bagdonas A., Boonsawat W., Gibbs M.R., Bousquet J., Bateman E.D., et al. Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. Prim Care Resp J 16 (2007) 155-161
47. Briggs A.H., Bousquet J., Wallace M.V., Busse W.W., Clark T.J., Pedersen S.E., et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 61 (2006) 531-536
48. Boulet L.P., Becker A., Berube D., Beveridge R., and Ernst P. Canadian asthma consensus report, 1999. Canadian asthma consensus group. CMAJ 161 Suppl. (1999) S1-61
49. Lahdensuo A., Haahtela T., Herrala J., Kava T., Kiviranta K., Kuusisto P., et al. Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ 316 (1998) 1138-1139
50. Gibson P.G., Powell H., Coughlan J., Wilson A.J., Abramson M., Haywood P., et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev (2003) CD001117
51. Boulet L.P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 113 (1998) 587-592
52. Hyland M.E., and Stahl E. Asthma treatment needs: a comparison of patients' and health care professionals' perceptions. Clin Ther 26 (2004) 2141-2152
53. Barnes N.C. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J 16 (2007) 149-154
54. Lai C.K., De Guia T.S., Kim Y.Y., Kuo S.H., Mukhopadhyay A., Soriano J.B., et al. Asthma control in the Asia-Pacific region: the asthma insights and reality in asia-pacific study. J Allergy Clin Immunol 111 (2003) 263-268
55. Desfougeres J.-L., Sohier B., Freedman D., Annunzuata K., Lemoine A., and Poterre M. Perception of asthma control by patients: results of a survey in 5 European countries. Eur Respir J 30 Suppl. 51 (2007) 249s
56. Price D., Canonica G.W., Dahl R., Baena-Cagnani C.E., Valovirta E.J., Blaiss M.S., et al. ABS008: asthma management and the PCP: findings of the global asthma physician and patient (GAPP) survey. Prim Care Respir J 15 (2006) 187
57. Boonsawat W., Charoenratanakul S., Pothirat C., Sawanyawisuth K., Seearamroongruang T., Bengtsson T., et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 97 (2003) 1067-1074
58. Seberova E., and Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 94 (2000) 607-611
59. Palmqvist M., Arvidsson P., Beckman O., Peterson S., and Lotvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 14 (2001) 29-34
60. Palmqvist M., Ibsen T., Mellen A., and Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 160 (1999) 244-249
61. Rabe K.F., Pizzichini E., Stallberg B., Romero S., Balanzat A.M., Atienza T., et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 129 (2006) 246-256
62. Scicchitano R., Aalbers R., Ukena D., Manjra A., Fouquert L., Centanni S., et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 20 (2004) 1403-1418
63. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
64. Kuna P., Peters M.J., Manjra A.I., Jorup C., Naya I.P., Martinez-Jimenez N.E., et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 61 (2007) 725-736
65. Rabe K.F., Atienza T., Magyar P., Larsson P., Jorup C., and Lalloo U.G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368 (2006) 744-753
66. Vogelmeier C., D'Urzo A., Pauwels R., Merino J.M., Jaspal M., Boutet S., et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 26 (2005) 819-828
67. Bousquet J., Boulet L.P., Peters M.J., Magnussen H., Quiralte J., Martinez-Aguilar N.E., et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 101 (2007) 2437-2446
68. Balanag V.M., Yunus F., Yang P.C., and Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 19 (2006) 139-147
69. Papi A., Paggiaro P., Nicolini G., Vignola A.M., and Fabbri L.M. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 62 (2007) 1182-1188
70. Papi A., Paggiaro P.L., Nicolini G., Vignola A.M., and Fabbri L.M. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 29 (2007) 682-689
71. Sears M.R., Boulet L.P., Laviolette M., Fitzgerald J.M., Bai T., Kaplan A., et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 31 (2008) 982-989
72. Demoly P., Louis R., Soes-Petersen U., Naya I., Carlsheimer A., Worth H., et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med 103 (2009) 1623-1632 [Epub 2009 Sep 16]
73. Bateman E.D., Bousquet J., Busse W.W., Clark T.J., Gul N., Gibbs M., et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 63 (2008) 932-938
74. Aalbers R., Backer V., Kava T.T., Omenaas E.R., Sandstrom T., Jorup C., et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 20 (2004) 225-240
75. Buhl R., and Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin 23 (2007) 1867-1878
76. Bateman E.D., Reddel H.K., Peterson S., Eriksson G., and O'Byrne P.M. Asthma Control Questionnaire score (ACQ-5) predicts future risk of exacerbations. Eur Respir J 34 Suppl. 53 (2009) 332s
77. Bateman E.D. Stability of overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy. Eur Respir J 34 Suppl. 53 (2009) 332s
78. Sears M.R., and Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 103 (2009) 1960-1968
79. Douma W.R., Kerstjens H.A., Rooyackers J.M., Koeter G.H., and Postma D.S. Risk of overtreatment with current peak flow criteria in self-management plans. Dutch CNSLD study group. Chronic non-specific lung disease. Eur Respir J 12 (1998) 848-852
80. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
81. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
82. Sears M.R., Ottosson A., Radner F., and Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 33 (2009) 21-32
83. Price D., Wiren A., and Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 62 (2007) 1189-1198
84. Johansson G., Andreasson E.B., Larsson P.E., and Vogelmeier C.F. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 24 (2006) 695-708
85. Bousquet J., Miravitlles M., and Wirén A. Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment. Eur Respir J 30 (2007) P1185
86. Symbicort prescribing information. Available at: http://www.symbicort.com/article/11435.aspx [accessed 19.11.07].
87. Gibson P.G., and Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 59 (2004) 94-99
88. Papi A., Canonica G.W., Maestrelli P., Paggiaro P., Olivieri D., Pozzi E., et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 356 (2007) 2040-2052
89. Milgrom H., Fowler-Taylor A., Fernandez-Vidaurre C., and Jayawardene S. Safety of omalizumab therapy in children with allergic asthma. Eur Respir J 34 (2009) 1214
90. Pires N., Amorim A., Gomes I., and Araujo I. Impact of omalizumab in patients with severe asthma. Eur Respir J 34 (2009) 1996
91. Brusselle G., Michils A., Louis R., Dupont L., Van de M.B., Delobbe A., et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med (2009)
92. Bousquet J., Kulus M., Fox H., Blogg M., Fowler-Taylor A., and Fernandez-Vidaurre C. Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline. Eur Respir J 34 (2009) 3281
93. Molimard M., Niven R., Buhl R., Le Gros V., Thielen A., Thirlwell J., et al. Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience. Eur Respir J 34 (2009) 1867
94. Reddel H.K., Taylor D.R., Bateman E.D., Boulet L.P., Boushey H.A., Busse W.W., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180 (2009) 59-99
95. Taylor D.R., Bateman E.D., Boulet L.P., Boushey H.A., Busse W.W., Casale T.B., et al. A new perspective on concepts of asthma severity and control. Eur Respir J 32 (2008) 545-554
96. Osman L.M., Calder C., Godden D.J., Friend J.A., McKenzie L., Legge J.S., et al. A randomised trial of self-management planning for adult patients admitted to hospital with acute asthma. Thorax 57 (2002) 869-874
97. Improving Chronic Illness Care. Available at: http://www.improvingchroniccare.org/index.html [accessed 02.01.08].